Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Pirtobrutinib, a non-covalent BTK inhibitor, enhances T-cell anti-tumor immunity in chronic lymphocytic leukemia (CLL)

View Full Paper
Ask AI
Bookmark
Share

Authors

VLVi Lam

Discussion

Loading...

Member takes

Overview

Treatment with pirtobrutinib improves T-cell activation and reduces apoptosis in chronic lymphocytic leukemia, suggesting immunomodulatory benefits.

Key Points

  • Pirtobrutinib enhances T-cell function without promoting apoptosis, improving immune responses in chronic lymphocytic leukemia.
  • In vitro studies revealed pirtobrutinib significantly upregulated IL-2 and Granzyme B secretion during T-cell activation.
  • Immunological synapse formation was enhanced by pirtobrutinib, indicating its potential in improving T-cell cytotoxicity against neoplastic cells.
  • These findings support the use of pirtobrutinib in combination therapies for lymphoid malignancies, highlighting its immunomodulatory roles.

Cite This Study

Vi Lam (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d857https://doi.org/10.1182/blood-2025-3878
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pirtobrutinib in Chronic Lymphocytic Leukemia: Navigating Resistance and the Personalisation of BTK-Targeted Therapy2025 · 4 citations
  2. 2Pirtobrutinib in Chronic Lymphocytic Leukemia: Navigating Resistance and the Personalisation of BTK-Targeted Therapy2025 · 4 citations
  3. 3Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor2025 · 2 citations
  4. 4Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study2025 · 6 citations
  5. 5Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study2025 · 4 citations